1-benzyl-3(S)-trifluoroacetylaminopyrrolidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzyl-3(S)-trifluoroacetylaminopyrrolidine
• 英文别名: N-[(3S)-1-benzylpyrrolidin-3-yl]-2,2,2-trifluoroacetamide
• 化学式: C₁₃H₁₅F₃N₂O
• 分子量: 272.27
• InChiKey: HFZWIEKMCFJKFB-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-benzyl-3(S)-trifluoroacetylaminopyrrolidine 、 二碳酸二叔丁酯 在 钯 氮 、 氢气 、 甲醇 、 二氯甲烷 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以to give 1-BOC-3(S)trifluoroacetylaminopyrrolidine的产率得到(S)-1-(tert-butoxycarbonyl)-3-(trifluoroacetamido)pyrrolidine
  参考文献：
  名称：

  Methods of treating insulin resistance syndrome and diabetes

  摘要：

  本发明涉及用于治疗患有胰岛素抵抗综合症和糖尿病的患者的方法，包括向该患者给予从腺苷和其类似物中衍生出的化合物的药物有效量，或其药物可接受的盐、药物可接受的前药、其N-氧化物、其水合物或其溶剂化物，或包含该化合物的药物组合物。

  公开号：

  US20030176390A1
• 作为产物：
  描述：

  (1S,2R,3S,4R)-2,3-dihydroxy-4-[6-[1-(4-trifluormethylpyridin-2-yl)pyrrolidin-3(S)-ylamino]purin-9-yl]cyclopentanecarboxylic acid isopropylamide 、 (S)-1-苄基-3-氨基吡咯烷 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-benzyl-3(S)-trifluoroacetylaminopyrrolidine
  参考文献：
  名称：

  Methods of treating insulin resistance syndrome and diabetes

  摘要：

  本发明涉及治疗胰岛素抵抗综合征和糖尿病的方法，包括向需要治疗的患者施用从腺苷和其类似物衍生的化合物的药效量，或其药用盐、药用前药、N-氧化物、水合物或溶剂化合物，或包含该化合物的药物组合物。

  公开号：

  US20030176390A1

文献信息

• Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties
  申请人：——

  公开号：US20020099030A1

  公开（公告）日：2002-07-25

  This invention relates to adenosine derivatives and analogues which possess biological activity and are useful as anti-hypertensive, cardioprotective, anti-ischemic, and antilipolytic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, and treating hyperlipidemia and hypercholesterolemia, and to methods and intermediates used in the preparation of such compounds.

  本发明涉及腺苷衍生物和类似物，具有生物活性，可用作抗高血压、心脏保护、抗缺血和抗脂解作用的药物，包括这些化合物的制药组合物，以及它们在治疗高血压、心肌缺血、改善缺血损伤和心肌梗死大小，治疗高脂血症和高胆固醇血症方面的用途，以及用于制备这些化合物的方法和中间体。
• Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
  申请人：Aventis Pharmaceuticals, Inc.

  公开号：US06376472B1

  公开（公告）日：2002-04-23

  A compound of the formula wherein K is N; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methylallyl, 2-butenyl, or cycloalkyl where the nitrogen of the ring of X is substituted by Y; E is O or S; Y is hydrogen, alkyl, aralkyl, substituted aralkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heterocyclylalkyl, or substituted heterocyclylalkyl; and n and p are independently 0, 1, 2, or 3, provided that n+p is at least 1; T is hydrogen, alkyl, alkylcarbonyl, alkylthiocarbonyl, halo, carboxyl, A and B are independently hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR′; or a pharmaceutically acceptable salt thereof, a pharmaceutic-ally acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

  该化合物的化学式为：其中K为N；Q为CH2或O；R6为氢、烷基、烯丙基、2-甲基烯丙基、2-丁烯基或环烷基，其中X的氮被Y取代；E为O或S；Y为氢、烷基、芳基烷基、取代芳基烷基、芳基、取代芳基、杂环烷基、取代杂环烷基、杂环烷基烷基或取代杂环烷基烷基；n和p独立地为0、1、2或3，但要求n+p至少为1；T为氢、烷基、烷基羰基、烷基硫代羰基、卤素、羧基；A和B独立地为氢、烷基、羟基烷基、烷氧基烷基或OR′。该化合物可以是其药用可接受盐、药用可接受前药、N-氧化物、水合物或溶剂合物。
• Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1258247A1

  公开（公告）日：2002-11-20

  The invention relates to the use of adenosine compounds described by formula I and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In the formula I K is N, N→O, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2, or 3, provided that n + p is at least 1; T is e.g hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR"; R' and R" are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.

  本发明涉及式 I 所述腺苷化合物及其某些衍生物用于生产治疗胰岛素抵抗综合征和糖尿病的药物。 及其某些衍生物用于生产治疗胰岛素抵抗综合征和糖尿病的药物。 在式 I 中 K 是 N、N→O 或 CH； Q 是 CH2 或 O； R6 是氢、烷基、烯丙基、2-甲基烯丙基、2-丁烯基或环烷基； E 是 O 或 S； Y 是氢、烷基、芳烷基或芳基； n 和 p 独立地为 0、1、2 或 3，条件是 n + p 至少为 1； T 例如是氢、烷基、酰基、硫代酰基、卤代酰基、羧基； R1、R2 和 R3 独立地是氢、烷基或环烷基； A 是氢、烷基、羟烷基、烷氧基烷基或 OR'； B 是氢、烷基、羟烷基、烷氧基烷基或 OR"； R'和 R "例如独立地为氢、烷基、芳烷基或氨基甲酰基。
• Enantiomeric impurities in chiral synthons, catalysts, and auxiliaries: Part 3
  作者：Ke Huang、Zachary S. Breitbach、Daniel W. Armstrong

  DOI：10.1016/j.tetasy.2006.10.014

  日期：2006.10

  The enantiomeric excess of chiral reagents used in asymmetric syntheses directly affects the reaction selectivity and product purity. In this work, 84 of the more recently available chiral compounds were evaluated to determine their actual enantiomeric composition. These compounds are widely used in asymmetric syntheses as chiral synthons, catalysts, and auxiliaries. These include chiral alcohols, amines, amino alcohols, amides, carboxylic acids, epoxides, esters, ketones, and oxolanes among other classes of compounds. All enantiomeric test results were categorized within five impurity levels (i.e., < 0.01%, 0.01-0.1%, 0.1-1%, 1-10%, and > 10%). The majority of the reagents tested were determined to have enantiomeric impurities over 0.01%, and two of them were found to contain enantiomeric impurities exceeding the 10% level. The most effective enantio selective analysis method was a GC approach using a Chiraldex GTA chiral stationary phase (CSP). This method worked exceedingly well with chiral amines and alcohols. (c) 2006 Elsevier Ltd. All rights reserved.
• EP0912520A4
  申请人：——

  公开号：EP0912520A4

  公开（公告）日：1999-10-06